Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 90

    1.

    TLE3 as a candidate biomarker of response to taxane therapy.

    Kulkarni SA, Hicks DG, Watroba NL, Murekeyisoni C, Hwang H, Khoury T, Beck RA, Ring BZ, Estopinal NC, Schreeder MT, Seitz RS, Ross DT.

    Breast Cancer Res. 2009;11(2):R17. Epub 2009 Mar 23.

    PMID:
    19309506
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.

    von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, Hilfrich J, Merkle E, Jackisch C, Costa SD, Caputo A, Kaufmann M; German Breast Group.

    Breast Cancer Res. 2008;10(2):R30. Epub 2008 Apr 1.

    PMID:
    18380893
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    3.

    Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP.

    Schneider J, Lucas R, Sánchez J, Ruibal A, Tejerina A, Martín M.

    Anticancer Res. 2000 Nov-Dec;20(6B):4373-7.

    PMID:
    11205274
    [PubMed - indexed for MEDLINE]
    4.

    HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma.

    Learn PA, Yeh IT, McNutt M, Chisholm GB, Pollock BH, Rousseau DL Jr, Sharkey FE, Cruz AB, Kahlenberg MS.

    Cancer. 2005 Jun 1;103(11):2252-60.

    PMID:
    15834928
    [PubMed - indexed for MEDLINE]
    Free Article
    5.

    Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer.

    Colleoni M, Gelber S, Coates AS, Castiglione-Gertsch M, Gelber RD, Price K, Rudenstam CM, Lindtner J, Collins J, Thürlimann B, Holmberg SB, Cortes-Funes H, Simoncini E, Murray E, Fey M, Goldhirsch A; International Breast Cancer Study Group.

    J Clin Oncol. 2001 Nov 1;19(21):4141-9.

    PMID:
    11689582
    [PubMed - indexed for MEDLINE]
    6.

    HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15.

    Paik S, Bryant J, Tan-Chiu E, Yothers G, Park C, Wickerham DL, Wolmark N.

    J Natl Cancer Inst. 2000 Dec 20;92(24):1991-8.

    PMID:
    11121461
    [PubMed - indexed for MEDLINE]
    Free Article
    7.

    High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy.

    Treré D, Brighenti E, Donati G, Ceccarelli C, Santini D, Taffurelli M, Montanaro L, Derenzini M.

    Ann Oncol. 2009 Nov;20(11):1818-23. Epub 2009 Jun 25.

    PMID:
    19556322
    [PubMed - indexed for MEDLINE]
    Free Article
    8.

    Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.

    Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM; GEICAM 9906 Study Investigators.

    J Natl Cancer Inst. 2008 Jun 4;100(11):805-14. Epub 2008 May 27.

    PMID:
    18505968
    [PubMed - indexed for MEDLINE]
    Free Article
    9.

    Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.

    Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.

    BMC Cancer. 2007 Apr 12;7:63.

    PMID:
    17430582
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    10.

    Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel.

    Torrisi R, Balduzzi A, Ghisini R, Rocca A, Bottiglieri L, Giovanardi F, Veronesi P, Luini A, Orlando L, Viale G, Goldhirsch A, Colleoni M.

    Cancer Chemother Pharmacol. 2008 Sep;62(4):667-72. Epub 2007 Dec 7.

    PMID:
    18064460
    [PubMed - indexed for MEDLINE]
    11.

    Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy.

    Schneider J, Gonzalez-Roces S, Pollán M, Lucas R, Tejerina A, Martin M, Alba A.

    Breast Cancer Res. 2001;3(3):183-91. Epub 2001 Feb 1.

    PMID:
    11305953
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    12.

    Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.

    Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Baronio R, Feyereislova A, Barton C, Valagussa P, Baselga J.

    Lancet. 2010 Jan 30;375(9712):377-84.

    PMID:
    20113825
    [PubMed - indexed for MEDLINE]
    13.

    C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer.

    Sjöström J, Collan J, von Boguslawski K, Franssila K, Bengtsson NO, Mjaaland I, Malmström P, Østenstad B, Wist E, Valvere V, Bergh J, Skiöld-Petterson D, Saksela E, Blomqvist C.

    Eur J Cancer. 2002 Mar;38(4):535-42.

    PMID:
    11872346
    [PubMed - indexed for MEDLINE]
    14.

    Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables.

    Ménard S, Valagussa P, Pilotti S, Gianni L, Biganzoli E, Boracchi P, Tomasic G, Casalini P, Marubini E, Colnaghi MI, Cascinelli N, Bonadonna G.

    J Clin Oncol. 2001 Jan 15;19(2):329-35.

    PMID:
    11208823
    [PubMed - indexed for MEDLINE]
    15.

    Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.

    Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.

    Breast Cancer Res Treat. 2009 Jul;116(1):131-43. Epub 2008 Jul 31.

    PMID:
    18668363
    [PubMed - indexed for MEDLINE]
    16.

    alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer.

    Ivanov O, Chen F, Wiley EL, Keswani A, Diaz LK, Memmel HC, Rademaker A, Gradishar WJ, Morrow M, Khan SA, Cryns VL.

    Breast Cancer Res Treat. 2008 Oct;111(3):411-7. Epub 2007 Oct 30.

    PMID:
    17968656
    [PubMed - indexed for MEDLINE]
    17.

    Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer.

    Jakesz R, Hausmaninger H, Haider K, Kubista E, Samonigg H, Gnant M, Manfreda D, Tschurtschenthaler G, Kolb R, Stierer M, Fridrik M, Mlineritsch B, Steindorfer P, Mittlböck M, Steger G.

    J Clin Oncol. 1999 Jun;17(6):1701-9.

    PMID:
    10561206
    [PubMed - indexed for MEDLINE]
    18.

    The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study.

    Wang L, Jiang Z, Sui M, Shen J, Xu C, Fan W.

    BMC Cancer. 2009 Jul 11;9:226.

    PMID:
    19591668
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    20.

    Changes in microvessel density as assessed by CD34 antibodies after primary chemotherapy in human breast cancer.

    Bottini A, Berruti A, Bersiga A, Brizzi MP, Allevi G, Bolsi G, Aguggini S, Brunelli A, Betri E, Generali D, Scaratti L, Bertoli G, Alquati P, Dogliotti L.

    Clin Cancer Res. 2002 Jun;8(6):1816-21.

    PMID:
    12060622
    [PubMed - indexed for MEDLINE]
    Free Article

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk